在用生物药物治疗的牛皮患者中,现实世界的切换模式和相关特征
Elizabeth Lazaridou1, Zoe Apalla2, Stylianos Ravanidis3
1Second Department of Dermatology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, 54124, Greece. bethlaz@auth.gr.
Archives of dermatological research
|January 28, 2025
概括
牛皮患者的生物治疗开关很常见,特别是在infliximab. 干白素抑制剂,如乌斯特基努马布和塞库基努马布显示更低的切换率,这表明更好的长期疗效.
科学领域:
- 皮肤病学和免疫学
- 医疗服务研究 医疗服务研究
背景情况:
- 牛皮的治疗涉及生物药物,但切换疗法是频繁的,并与较差的结果相关.
- 了解生物切换模式对于优化牛皮管理至关重要.
研究的目的:
- 分析希腊牛皮患者的生物切换模式.
- 为了确定影响牛皮的生物治疗变化的因素.
主要方法:
- 使用希腊国家数字处方数据库进行的回顾性队列研究.
- 包括6772名从未服用过生物素的牛皮病患者 (有或没有牛皮关节炎),在2016-2020年期间开始服用生物药物.
主要成果:
- 因弗利西马布显示了最高的转换率;乌斯特基努马布和塞库金努马布的转换率最低.
- 在12个月后,secukinumab和 brodalumab的切换/重新启动率最低.
- 同时患上牛皮关节炎和女性性别增加了切换风险;互白素抑制剂的切换风险低于阿达利木马布.
结论:
- 与传统药物相比,向介素的生物药物表现出较低的转换率.
- 早期考虑长期治疗方案至关重要,因为最初的过渡需要更长的时间.
- 同时的牛皮关节炎和患者的性别显著影响治疗结果,并应指导治疗选择.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
114
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
114
T Cell Types and Functions
942
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
942
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
141
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
141
Inflammatory Bowel Disease IV: Pharmacological Management
106
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
106
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
95
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
95
Psychosis: Goals of Pharmacotherapy
103
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
103


